BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 11857395)

  • 1. Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women.
    Talley LI; Grizzle WE; Waterbor JW; Brown D; Weiss H; Frost AR
    Int J Cancer; 2002 Mar; 98(1):118-27. PubMed ID: 11857395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of estrogen and progesterone receptors in human ductal invasive breast carcinoma not otherwise specified: is there any difference between premenopausal and postmenopausal women?
    Petricević J; Petković M; Jonjić N
    Acta Clin Croat; 2011 Jun; 50(2):169-75. PubMed ID: 22263379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
    Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas.
    Soslow RA; Carlson DL; Horenstein MG; Osborne MP
    Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of women with node negative breast cancer in the Auckland region.
    Lethaby AE; Mason BH; Harvey VJ; Holdaway IM
    N Z Med J; 1996 Sep; 109(1029):330-3. PubMed ID: 8862351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.
    Enger SM; Ross RK; Paganini-Hill A; Carpenter CL; Bernstein L
    Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):681-7. PubMed ID: 10919738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The estrogen receptor/progesterone receptor quotient as an index of the transcriptional activity of estrogen receptors in breast cancer].
    Navarro MA; Díez Gibert O; Fernández-Montolí ME; Rosel P; Bonnin MR
    Med Clin (Barc); 1995 May; 104(18):681-2. PubMed ID: 7769876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Subtypes and Prognostic Factors among Premenopausal and Postmenopausal Thai Women with Invasive Breast Cancer: 15 Years Follow-up Data.
    Tubtimhin S; Promthet S; Suwanrungruang K; Supaattagorn P
    Asian Pac J Cancer Prev; 2018 Nov; 19(11):3167-3174. PubMed ID: 30486605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction.
    Ning L; Liu Y; He X; Han R; Xin Y; Zhao J; Liu X
    Am J Clin Oncol; 2024 May; 47(5):228-238. PubMed ID: 38131531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Estrogen and progesterone receptors of primary breast carcinoma and their axillary lymph node metastases--immunohistochemical investigations of routine formalin-fixed paraffin-embedded tissue].
    Schulze MH; Buchmann J
    Zentralbl Gynakol; 2000; 122(2):92-5. PubMed ID: 10721188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of breast cancer subtypes and body mass index.
    Petekkaya I; Sahin U; Gezgen G; Solak M; Yuce D; Dizdar O; Arslan C; Ayyildiz V; Altundag K
    Tumori; 2013; 99(2):129-33. PubMed ID: 23748802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer.
    Rudolph P; Kühling H; Alm P; Fernö M; Baldetorp B; Olsson H; Parwaresch R
    Int J Cancer; 2003 Jul; 105(5):674-80. PubMed ID: 12740917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer.
    Fuckar D; Dekanić A; Stifter S; Mustać E; Krstulja M; Dobrila F; Jonjić N
    Int J Surg Pathol; 2006 Jan; 14(1):49-55. PubMed ID: 16501835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women.
    Biglia N; Peano E; Sgandurra P; Moggio G; Pecchio S; Maggiorotto F; Sismondi P
    Gynecol Endocrinol; 2013 Mar; 29(3):263-7. PubMed ID: 23174088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
    Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
    J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal receptor determination of 1,052 Chinese breast cancers.
    Chow LW; Ho P
    J Surg Oncol; 2000 Nov; 75(3):172-5. PubMed ID: 11088048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.